Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Emery

Showing results (61-70 of 732) with videos related to

Pageof 74
Sort By:
Rheumatology (Oxford, England)|November 11, 2020
Treating rheumatoid arthritis to an imaging target produces better outcomes, or does it?Kulveer Mankia, Hanna Gul, Paul Emery
Lancet (London, England)|May 4, 2005
Increased risk of cardiovascular events with coxibs and NSAIDsPaul Emery, Andrew Moore, Chris Hawkey
Arthritis Care & Research|October 29, 2010
Care needs to be taken when reviewing malignancy data reported from observational studies: comment on the article by Onel and OnelXavier Mariette, Alan Reynolds, Paul Emery
Arthritis Research & Therapy|June 2, 2007
Aspects of early arthritis. Biological therapy in early arthritis--overtreatment or the way to go?Kei Ikeda, Sally Cox, Paul Emery
Revista Brasileira De Reumatologia|December 3, 2010
2010 ACR-EULAR classification criteria for rheumatoid arthritisEdith Villeneuve, Jackie Nam, Paul Emery
Rheumatology (Oxford, England)|March 12, 2021
COVID-19 vaccination and antirheumatic therapyJack Arnold, Kevin Winthrop, Paul Emery
Drugs|March 5, 2013
Targeting interleukin-6 in rheumatoid arthritisMd Yuzaiful Md Yusof, Paul Emery
The New England Journal of Medicine|July 26, 2023
Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis. ReplyJay Tuttle, Paul Emery, Ajay Nirula
Annals of the Rheumatic Diseases|December 10, 2016
Identifying arthralgia suspicious for progression to rheumatoid arthritisKulveer Mankia, Jackie Nam, Paul Emery
Expert Opinion on Biological Therapy|December 15, 2011
Certolizumab pegol for the treatment of rheumatoid arthritisSarah Horton, Ceara Walsh, Paul Emery
Pageof 74

Showing results (61-70 of 732) with videos related to

Sort By:
Pageof 74
Rheumatology (Oxford, England)|November 11, 2020
Treating rheumatoid arthritis to an imaging target produces better outcomes, or does it?Kulveer Mankia, Hanna Gul, Paul Emery
Lancet (London, England)|May 4, 2005
Increased risk of cardiovascular events with coxibs and NSAIDsPaul Emery, Andrew Moore, Chris Hawkey
Arthritis Care & Research|October 29, 2010
Care needs to be taken when reviewing malignancy data reported from observational studies: comment on the article by Onel and OnelXavier Mariette, Alan Reynolds, Paul Emery
Arthritis Research & Therapy|June 2, 2007
Aspects of early arthritis. Biological therapy in early arthritis--overtreatment or the way to go?Kei Ikeda, Sally Cox, Paul Emery
Revista Brasileira De Reumatologia|December 3, 2010
2010 ACR-EULAR classification criteria for rheumatoid arthritisEdith Villeneuve, Jackie Nam, Paul Emery
Rheumatology (Oxford, England)|March 12, 2021
COVID-19 vaccination and antirheumatic therapyJack Arnold, Kevin Winthrop, Paul Emery
Drugs|March 5, 2013
Targeting interleukin-6 in rheumatoid arthritisMd Yuzaiful Md Yusof, Paul Emery
The New England Journal of Medicine|July 26, 2023
Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis. ReplyJay Tuttle, Paul Emery, Ajay Nirula
Annals of the Rheumatic Diseases|December 10, 2016
Identifying arthralgia suspicious for progression to rheumatoid arthritisKulveer Mankia, Jackie Nam, Paul Emery
Expert Opinion on Biological Therapy|December 15, 2011
Certolizumab pegol for the treatment of rheumatoid arthritisSarah Horton, Ceara Walsh, Paul Emery
Pageof 74